The Obesity/Diabetes Epidemic: Adiposopathy & ‘Obesity’- The New Disease! Weight Management in Obesity and DM: Emphasis on New Medical Therapies Stan Schwartz.

Slides:



Advertisements
Similar presentations
1 Prediabetes Screening and Monitoring. 2 Prediabetes Epidemiologic evidence suggests that the complications of T2DM begin early in the progression from.
Advertisements

Assessment of Overweight and Obesity and the Need for Weight Loss Dr. David L. Gee FCSN/PE 446 Nutrition, Weight Control & Exercise.
Definitions Body Mass Index (BMI) describes relative weight for height: weight (kg)/height (m 2 ) Overweight = 25–29.9 BMI Obesity = >30 BMI.
Cardio-Metabolic Syndrome Guidelines on Education, Detection and Early Treatment  Heval Mohamed Kelli, PGY-2 Emory Internal Medicine Residency no conflict.
SUPERSIZED NATION By Jennifer Ericksen August 24, 2007.
Physical Activity and Weight Loss ACSM, Weight Gain Physical activity will prevent weight gain – PA of 150 to 250 min. wk -1 with an energy equivalent.
OBESITY and CHD Nathan Wong. OBESITY AHA and NIH have recognized obesity as a major modifiable risk factor for CHD Obesity is a risk factor for development.
Slide Source: Lipids Online Slide Library 56 healthy premenopausal obese women (aged 25–44 years) compared with 40 age-matched nonobese.
Special Diabetes Program for Indians Competitive Grant Program SPECIAL DIABETES PROGRAM FOR INDIANS Competitive Grant Program Clinical Goals for the Healthy.
Effectiveness of interactive web-based lifestyle program on prevention of cardiovascular diseases risk factors in patient with metabolic syndrome: a randomized.
Facts and Fiction about Type 2 Diabetes Michael L. Parchman, MD Department of Family & Community Medicine September 2004.
Only You Can Prevent CVD Matthew Johnson, MD. What can we do to prevent CVD?
Exercise the Medicine of Choice Reducing Cardiovascular Risk Dr. Lynn Panton Florida State University College of Human Sciences Department of Nutrition,
HEALTHY EATING And LIVING Kenneth E. Nixon MD. Problem Overweight and Obesity 97 million adults are overweight or obese Medical Problems Associated with.
Minimally Invasive Surgery Symposium Modest Weight Loss in T2 DM: Lessons from the Look AHEAD Trial Donna H. Ryan, MD Pennington Biomedical Research Center.
{ A Novel Tool for Cardiovascular Risk Screening in the Ambulatory Setting Guideline-Based CPRS Dialog Adam Simons MD.
Role of Rosuvastatin in the Treatment of Dyslipidemia
Obesity M.A.Kubtan MD - FRCS M.A.Kubtan1. 2  Pulmonary Disease  Fatty Liver Disease  Orthopedic Disorders  Gallbladder Disease  Psychological Impact.
METABOLIC Syndrome: a Global Perspective
KORIN M. TRUMPIE Evidence Based Medicine Spring 2009.
William B. Kannel, MD, FACC Former Director, Framingham Heart Study
Physical Wellness Health A / B. Disease Prevention Regular physical activity lowers your risk of many chronic and disabling disease. Why? What is a chronic.
Medical Management of obesity Perinatal ANGELS Conference Feb 17, 2005 Philip A. Kern.
Modern Management of Cholesterol in the High-Risk Patient.
Leveraging Weight Loss in the Treatment of Type 2 Diabetes Part 1 of 4.
VA/DoD 2006 Clinical Practice Guideline For Screening and Management of Overweight and Obesity Guideline Summary: Key Elements.
The Obesity/Diabetes Epidemic: Perspectives, Consequences, Prevention, Treatment Stan Schwartz MD, FACP, FACE Private Practice, Ardmore Obesity Program.
Type 2 Diabetes – A Global Epidemic Arya M Sharma, MD, FRCP(C) Professor of Medicine Research Chair for Obesity Research & Management University of Alberta.
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015 Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical Associate Professor.
The Obesity/Diabetes Epidemic: Perspectives, Consequences, Prevention, Treatment Stan Schwartz MD, FACP, FACE Private Practice, Ardmore Obesity Program.
The Obesity/Diabetes Epidemic: Perspectives, Consequences, Prevention, Treatment Stan Schwartz MD, FACP, FACE Private Practice, Ardmore Obesity Program.
The Obesity/Diabetes Epidemic: Adiposopathy & ‘Obesity’- The New Disease! Weight Management in Obesity and DM: Emphasis on New Medical Therapies Stan Schwartz.
The Obesity/Diabetes Epidemic: Adiposopathy & Obesity- The New Disease! Dx & (Rx) of Insulin Resistance & early DM Part 3 Stan Schwartz MD, FACP, FACE.
The Obesity/Diabetes Epidemic: Adiposopathy & ‘Obesity’- The New Disease! Weight Management in Obesity and DM: Emphasis on New Medical Therapies Stan Schwartz.
The Obesity/Diabetes Epidemic: Adiposopathy & Obesity- The New Disease! Dx & (Rx) of Insulin Resistance & early DM Stan Schwartz MD, FACP, FACE Private.
Metabolic syndrome from a gender and cardiovascular perspective Eva Swahn.
The Obesity/Diabetes Epidemic: Adiposopathy & ‘Obesity’- The New Disease! Weight Management in Obesity and DM: Emphasis on New Medical Therapies Stan Schwartz.
The Obesity/Diabetes Epidemic: Adiposopathy & Obesity- The New Disease! Dx & (Rx) of Insulin Resistance & early DM Part 4 Stan Schwartz MD, FACP, FACE.
A Diabetes Outcome Progression Trial
IR and Hyperinsulinemia Insulin Resistance: A Survival Mechanism, Gone Awry Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical.
The Obesity/Diabetes Epidemic: Adiposopathy & Obesity- The New Disease! Dx & (Rx) of Insulin Resistance & Early DM (Part 1) Stan Schwartz MD, FACP, FACE.
 GLP-1 agonists have shown to help patients lose weight  Mechanism of GLP-1 agonists  Cardioprotective effects of GLP-1 agonists  GLP-1 agonists and.
Leveraging Weight Loss in the Treatment of Type 2 Diabetes Part 2 of 4.
The Obesity/Diabetes Epidemic: Adiposopathy & ‘Obesity’- The New Disease! Weight Management in Obesity and DM: Emphasis on New Medical Therapies Stan Schwartz.
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015
The Obesity/Diabetes Epidemic: Perspectives, Consequences, Prevention, Treatment Stan Schwartz MD, FACP, FACE Private Practice, Ardmore Obesity Program.
The Obesity/Diabetes Epidemic: Adiposopathy & ‘Obesity’- The New Disease! Weight Management in Obesity and DM: Emphasis on New Medical Therapies Stan Schwartz.
The Obesity/Diabetes Epidemic: Adiposopathy & Obesity- The New Disease! Dx & (Rx) of Insulin Resistance & early DM (Part 2) Stan Schwartz MD, FACP, FACE.
The Obesity/Diabetes Epidemic: Adiposopathy & Obesity- The New Disease! Dx & (Rx) of Insulin Resistance & Early DM Part 5 Stan Schwartz MD, FACP, FACE.
The Obesity/Diabetes Epidemic: Adiposopathy & Obesity- The New Disease! Dx & (Rx) of Insulin Resistance & early DM Stan Schwartz MD, FACP, FACE Private.
The Obesity/Diabetes Epidemic: Adiposopathy & ‘Obesity’- The New Disease! Weight Management in Obesity and DM: Emphasis on New Medical Therapies Stan Schwartz.
The Obesity/Diabetes Epidemic: Perspectives, Consequences, Prevention, Treatment Stan Schwartz MD, FACP, FACE Private Practice, Ardmore Obesity Program.
CHAPTER 7: Obesity in Women. Introduction 68% of U.S. population is overweight or obese. Resulting medical and psychosocial difficulties can be debilitating.
The Obesity/Diabetes Epidemic: Perspectives, Consequences, Prevention, Treatment Stan Schwartz MD, FACP, FACE Private Practice, Ardmore Obesity Program.
Risk Factor Modification in CCR. How does CR work?
Date of download: 5/31/2016 From: Metabolic Risk Factors Worsen Continuously across the Spectrum of Nondiabetic Glucose Tolerance: The Framingham Offspring.
Circulation. 2014;129: Association Between Plasma Triglycerides and High-Density Lipoprotein Cholesterol and Microvascular Kidney Disease and Retinopathy.
Date of download: 7/5/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Effects of High vs Low Glycemic Index of Dietary Carbohydrate.
Date of download: 9/17/2016 From: Effectiveness of Primary Care–Relevant Treatments for Obesity in Adults: A Systematic Evidence Review for the U.S. Preventive.
What Is the Disease of Obesity?
HDL cholesterol and cardiovascular risk Epidemiological evidence
Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults Risks and Assessment NHLBI Obesity Education.
HDL cholesterol and cardiovascular risk
Screening and Monitoring
What Is the Disease of Obesity?
Type 2 diabetes: Overlap of clinical conditions
Goals & Guidelines A summary of international guidelines for CHD
Change in (A) total cholesterol; (B) LDL-cholesterol; (C) HDL-cholesterol and (D) triglycerides over 5 years in response to 12-week intensive lifestyle.
Obesity Eppie Habashi.
RECORD Study: Enrollment and Outcomes
Presentation transcript:

The Obesity/Diabetes Epidemic: Adiposopathy & ‘Obesity’- The New Disease! Weight Management in Obesity and DM: Emphasis on New Medical Therapies Stan Schwartz MD, FACP, FACE Private Practice, Ardmore Obesity Program Cardiometabolic Diabetes Center and Affiliate, Main Line Health System Emeritus, Clinical Associate Professor University of Pennsylvania Part 2

Health Benefits of Modest Weight Loss (5-10%)  Decreased cardiovascular risk  Decreased blood glucose and insulin levels  Decreased blood pressure  Decreased LDL and triglycerides, increased HDL  Decrease in severity of sleep apnea  Reduced symptoms of degenerative joint disease  Improvement in gynecologic conditions  Multiple cardiovascular risk factors and other complications can be improved. Source: The Practical Guide to the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults..

Insulin Sensitivity Improves With Weight Loss in Patients With Type 2 Diabetes *P<0.01 vs before. Wing et al. Arch Intern Med 1987;147:1749. Insulin (pmol/L) Weight Loss at 1 Year (%) * * * Before 0– –6.9  –14.0

Plasma Lipids Improve With Weight Loss Meta-analysis of 70 Clinical Trials Dattilo et al. Am J Clin Nutr 1992;56: Total Cholesterol LDL-CTG HDL-C (weight stable) HDL-C (actively losing)  mmol/L per kg of Weight Loss  mg/dL per kg of Weight Loss * * * * * *P  LDL-C=low density lipoprotein cholesterol; HDL-C=high-density lipoprotein cholesterol; TG=triglycerides.

Relationship Between Change in Weight and Blood Pressure: Trials of Hypertension Prevention II Stevens et al. Ann Intern Med 2001;134:1. Change in Weight (kg) Change in Blood Pressure (mm Hg) Quintile of Weight Change Diastolic Systolic

Effect of Weight Change on Apnea-Hypopnea Index (AHI) Peppard et al. JAMA 2000;284:3015. Change in Body Weight (%) -20 to <-10 (n=22) -10 to <-5 (n=39) -5 to <+5 (n=371) +5 to <+10 (n=179) +10 to +20 (n=79) Mean Change in AHI (Events/h)

Reduction in Body Weight (%) Reduction in Body Weight (%) Change in FMD of Brachial Artery (%) R 2 = p = % Relation Between %Weight Loss and Endothelial Function Hamdy et al Diabetes Care 2003;26:

p<0.05 NS NS p<0.001 p<0.01 NS IL-6 TNF-  hCRP PAI-1 Leptin % Change From Baseline Monzillo LU Obes Res. 2003;11(9): Hamdy O et al. Diabetes Care. 2003;26: Adiponectin Benefits of weight reduction on cytokines in type 2 DM and in pre-diabetes

Relationship Between Weight Change and CHD Risk Factor Sum: Framingham Offspring Study *P<0.002 vs baseline. Wilson et al. Arch Intern Med 1999;159:1104. Weight Change During 16-y Follow-up Men Women Change in Risk Factor Sum (%) * * * * Loss  2.25 kg Gain  2.25 kg +37% –40% –48% +20%

Weight Loss Can Increase Life Expectancy in Obese Patients With Type 2 Diabetes Weight Loss in First 12 Months (kg) Life Expectancy (y) Lean et al. Diabet Med 1990;7:228.

Outline Epidemiology and Economics of obesity/diabetes Perspectives on Obesity Consequences of Obesity, Prediabetes, Obesity Obesity/ Diabetes Risk Factors, Obesity/ Diabetes Onset can be Prevented or Delayed – Early Risk Identification and Intervention. Medical Benefits to Weight Loss Treatment- –Basics, Generalities –Obesity Lifestyle- Diet, Activity, Behavior Medications –Weight Control, WEIGHT REDUCTION in DIABETES

Weight Loss Goals in Lifestyle Modification “ The initial goal of weight loss therapy for overweight patients is a reduction in body weight of about 10 percent….Moderate weight loss of this magnitude can significantly decrease the severity of obesity-associated risk factors. ” Most patients desire much greater weight losses. Higher goals may be related to more weight loss. NIH/NHLBI, NAASO. The Practical Guide: Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. Bethesda, MD: NIH, 2000.